Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 and Pembrolizumab in Advanced or Recurrent Endometrial Cancer
NCT05761951Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirexatamab in endometrial cancer (EC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Incidence of Adverse Events at 1 year. Started Aug 2023; status: active, not recruiting.
02
Drugs
sirexatamab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05761951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761951.